T cells play an important role in controlling tumor growth and mediating tumor rejection in vivo. Identification of several classes of MHC class I-restricted tumor antigens from melanoma as well as other cancers has led to the initiation of clinical trials using these identified T cell epitopes. While these studies hold the promise of effective treatment of patients with metastatic cancer, the exclusive use of CD8+ T cells may not generate an optimal anti-tumor immunity. Increasing evidence from both human and animal studies indicates that CD4+ T (helper) cells play a central role in initiating and maintaining the host immune responses against cancer, but the lack of such knowledge of MHC class II-restricted tumor antigens is a major hurdle for developing more effective cancer vaccines. The long-range goal of this study is to dissect immune components of tumor immunity, to understand the mechanism by which CD4+ T cells regulate immune responses, and to develop effective cancer vaccines for the prevention and therapeutic treatment of patients with cancer. The central hypothesis is that MHC class II-restricted tumor antigens induce tumor-reactive CD4+ T cells, which provide critical help for priming and activation of CD8 T cells, the major effector cells for tumor destruction. Thus, the combination of CD4+ with CD8+ T cell epitopes will further augment anti-tumor immune responses. The rationale for the proposed research is that, once it is known how tumor immunity is regulated by MHC class II restricted CD4+ T cells, CD4+ T cell helper peptides/antigens will be effectively incorporated in cancer vaccine regimen for the preventive and treatment of patients with cancer. The proposed research is built on a novel genetic system we originally developed. We have generated unique resouces (tumor-specific CD4+ T cell lines or clones), and established experimental animal models. To test our central hypothesis, we will further improve the genetic cloning system and identify MHC class II-restricted tumor antigens as immune targets. We will evaluate the immunogenicity and role of DR2-restricted T helper peptides in protective immunity in DR2-Tg mice. We will also develop novel vaccine strategies to enhance CD4+ T cell responses in an attempt to eradicate tumor. It is anticipated that these studies will advance the field of immunotherapy of cancer and provide a foundation of the development of novel approaches for effective cancer vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA090327-04
Application #
6832780
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Howcroft, Thomas K
Project Start
2001-12-12
Project End
2006-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
4
Fiscal Year
2005
Total Cost
$301,376
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Ning, Bo; Zhao, Wei; Qian, Chen et al. (2017) USP26 functions as a negative regulator of cellular reprogramming by stabilising PRC1 complex components. Nat Commun 8:349
Jin, Shouheng; Tian, Shuo; Chen, Yamei et al. (2016) USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin-1. EMBO J 35:866-80
Qin, Yunfei; Liu, Qingxiang; Tian, Shuo et al. (2016) TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3? to TBK1. Cell Res 26:613-28
Ning, Bo; Li, Wenyuan; Zhao, Wei et al. (2016) Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) 48:97-109
Yang, Zhifen; Xian, Huifang; Hu, Jiajia et al. (2015) USP18 negatively regulates NF-?B signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Sci Rep 5:12738
Burchfield, Jana S; Li, Qingtian; Wang, Helen Y et al. (2015) JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol 67:148-57
Wu, Jian; Cai, Baowei; Sun, Wenxiang et al. (2015) Genome-wide Analysis of Host-Plasmodium yoelii Interactions Reveals Regulators of the Type I Interferon Response. Cell Rep 12:661-72
Wang, Mingjun; Yin, Bingnan; Wang, Helen Y et al. (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:1265-78
Cui, Jun; Song, Yanxia; Li, Yinyin et al. (2014) USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. Cell Res 24:400-16
Wu, Jian; Tian, Linjie; Yu, Xiao et al. (2014) Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. Proc Natl Acad Sci U S A 111:E511-20

Showing the most recent 10 out of 32 publications